Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Amarantus Bioscience Holdi AMBS
(Total Views: 395)
Posted On: 12/02/2018 2:37:11 PM
Post# of 30066
Avatar
Posted By: freegriff
Optimal control of treatments for retinitis pigmentosa presentation at NIMBios @UTennessee. Good engaged audience.
https://www.youtube.com/watch?v=3OeCttRMVDk

Notes:
-40% of rods and cones rescued by RdCVF

-for MANF compared to Neves et al. mouse RP paper.http://science.sciencemag.org/content/353/6294/aaf3646.long

-Ran 3 models. 55-65% rescue rate depending on model, compared well to Neves paper

-suggests ideal treatment combines both RdCVF and MANF

-they're doing further evaluation of combined treatment, and periodic dose treatment. MANF results under review, soon to be published, author notes in Q/A that he's reached out to Amarantus and they're waiting for study review before disclosing

-I have referred the presentation to a friend in the field for further elucidation

-My further observation is this study comes from a guy based out of Shippenburg University. The list of connections in Pennsylvania, Coeptis, Shakkah Fattah, etc continues to grow. I know G's father in law is some big dentist/ortho guy in Pennsylvania. You wonder how much that network is helping. Keeping that in mind with JLABS Philly.













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site